Ultrasonography of liver tumors

DGAP-News: Study reported in BMC Gastroenterology shows significantly better performance characteristics of Epigenomics' liver cancer panel compared to the current standard of care for the early detection of HCC

Retrieved on: 
Tuesday, April 6, 2021

In addition, HCC is considered the second leading cause of cancer-related deaths world-wide with more than 780,000 deaths annually.

Key Points: 
  • In addition, HCC is considered the second leading cause of cancer-related deaths world-wide with more than 780,000 deaths annually.
  • The study compared patients with cirrhosis who had early-stage treatable liver cancer with patients having cirrhosis but no cancer.
  • The current standard of care for HCC surveillance is ultrasound plus AFP with a sensitivity of 63% and a specificity of 84%.
  • Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer.

Liver Cancer Tumors Appear to Be Resistant to Immunotherapy in Patients With Underlying Non-alcoholic Steatohepatitis (NASH)

Retrieved on: 
Wednesday, March 24, 2021

The researchers led a large international collaboration to investigate immunotherapy's effect on hepatocellular carcinoma (HCC), a deadly liver cancer, caused by NASH.

Key Points: 
  • The researchers led a large international collaboration to investigate immunotherapy's effect on hepatocellular carcinoma (HCC), a deadly liver cancer, caused by NASH.
  • "These results also highlight the need for refined therapeutic strategies aimed at treating both the tumor as well as the microenvironment associated with distinct underlying liver disease."
  • While immunotherapy has clinical benefit for hepatocellular carcinoma, this study's findings are important because a quarter of all HCC patients have NASH.
  • The meta-analysis in this study was conducted on three high-quality phase 3 trials that included more than 1,600 HCC patients treated with anti-PD1 immunotherapy.

Hepatocellular Carcinoma Epidemiology Forecast to 2029: Focus on US, France, Germany, Italy, Spain, UK, Japan, and Urban China - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 13, 2021

The "Hepatocellular Carcinoma - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hepatocellular Carcinoma - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The report includes the diagnosed incident cases and five-year diagnosed prevalent cases of HCC in these markets from 2019-2029.
  • Hepatocellular carcinoma (HCC) is a common type of primary liver cancer that arises from the hepatocytes in the liver.
  • HCC is classified by various staging systems such as the Barcelona Clinic Liver Cancer (BCLC) stage and Child Pugh stages.

Positive Data Presented on Helio Health Liver Test for the Detection of Hepatocellular Carcinoma (HCC) Advances Product Development

Retrieved on: 
Friday, November 13, 2020

Data from this study suggest that the Helio Liver Test, a multi-analyte HCC-specific blood test, provides greater sensitivity and specificity for the detection of early-stage HCC and disease surveillance in high-risk communities compared to current screening modalities.

Key Points: 
  • Data from this study suggest that the Helio Liver Test, a multi-analyte HCC-specific blood test, provides greater sensitivity and specificity for the detection of early-stage HCC and disease surveillance in high-risk communities compared to current screening modalities.
  • Ultrasound, the current standard of care for early-stage HCC detection, has approximately 47% (95% CI: 33-61%) sensitivity.
  • These positive data provide further evidence of the Helio Liver Test's ability to provide earlier detection with greater accuracy for liver cancer and enable groundbreaking advances in the detection and management of this growing disease," said Kenneth Chahine, Ph.D., J.D., Chief Executive Officer of Helio Health.
  • Helio Health is an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw.

TriSalus™ Life Sciences Launches the new TriNav™ Infusion System, an Innovative Solution Designed to Overcome Infusion Barriers within Solid Tumors

Retrieved on: 
Monday, January 13, 2020

TriSalusTM Life Sciences (TriSalus), a company committed to transforming outcomes for patients with solid tumors, today announced the launch of its TriNav Infusion System (TriNav).

Key Points: 
  • TriSalusTM Life Sciences (TriSalus), a company committed to transforming outcomes for patients with solid tumors, today announced the launch of its TriNav Infusion System (TriNav).
  • Powered by its proprietary Pressure-Enabled Drug DeliveryTM (PEDD) approach with SmartValveTM technology, TriNav is designed to help overcome the infusion barriers that limit therapeutic uptake in solid tumors, including hepatocellular carcinoma (HCC) and liver metastases.2,3
    This press release features multimedia.
  • It delivers radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.15
    TriSalusTM Life Sciences is dedicated to improving patient outcomes in pancreatic and other highly intractable solid tumors.
  • This innovative approach has the potential to allow for the administration of multiple mechanisms that can work together to overcome inherent immune suppression within the solid tumor microenvironment.

Simple CEUS Scan Helps Diagnose Liver Cancer When MRI is Uncertain

Retrieved on: 
Thursday, September 5, 2019

A new study shows that a simple, non-invasive contrast enhanced ultrasound (CEUS) scan can be more accurate and reliable than a more expensive MRI procedure for diagnosis of liver tumors and determining whether they are cancerous.

Key Points: 
  • A new study shows that a simple, non-invasive contrast enhanced ultrasound (CEUS) scan can be more accurate and reliable than a more expensive MRI procedure for diagnosis of liver tumors and determining whether they are cancerous.
  • Dr. Wilson said that CEUS scans demonstrated more than 81% sensitivity and 100% specificity in diagnosing cancerous liver tumors where MRI was inconclusive.
  • MRI currently is the mainstay for liver imaging in North America but inconclusive results are common, according to Dr. Wilson.
  • CEUS does not expose patients to ionizing radiation and ultrasound contrast agents present no known risk of kidney or liver damage.

CEUS Safely Assesses Suspected Liver Tumors in Pregnant Women

Retrieved on: 
Thursday, September 5, 2019

A team from the University of Munich in Germany has safely performed contrast enhanced ultrasound (CEUS) scans in pregnant women with suspected liver tumors, and found that this minimally-invasive diagnostic imaging tool provided information essential for their care.

Key Points: 
  • A team from the University of Munich in Germany has safely performed contrast enhanced ultrasound (CEUS) scans in pregnant women with suspected liver tumors, and found that this minimally-invasive diagnostic imaging tool provided information essential for their care.
  • Ultrasound contrast agents are approved throughout much of the world for imaging adults and children, but they are not yet approved for imaging pregnant women.
  • The retrospective study used CEUS to evaluate liver lesions of unknown origin in six pregnant women.
  • CEUS is a very safe and useful imaging modality, and was extremely well tolerated by our pregnant patients, Professor Clevert said.

The global liver cancer diagnostics market size is expected to reach USD 15.4 billion by 2025

Retrieved on: 
Tuesday, February 19, 2019

Liver Cancer Diagnostic Market Size, Share & Trends Analysis Report By Screening Type (Biopsy, Endoscopy, Laboratory Tests, Imaging), By Region (North America, APAC, Europe), And Segment Forecasts, 2019 - 2025

Key Points: 
  • Liver Cancer Diagnostic Market Size, Share & Trends Analysis Report By Screening Type (Biopsy, Endoscopy, Laboratory Tests, Imaging), By Region (North America, APAC, Europe), And Segment Forecasts, 2019 - 2025
    The global liver cancer diagnostics market size is expected to reach USD 15.4 billion by 2025, according to a new report by Grand View Research, Inc.
  • Rise in disease incidence coupled with growing demand for novel diagnosis products are thrusting the growth of the market.
  • Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer in adults.
  • These factors along with high unmet needs are expected to propel the growth of liver cancer diagnostics market through the forecast period.